Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 2
2003 7
2004 3
2005 5
2006 4
2007 6
2008 2
2009 2
2010 7
2011 2
2012 7
2013 5
2014 8
2015 17
2016 7
2017 4
2018 4
2019 1
2020 5
2021 8
2022 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis.
Yamashita D, Suehiro S, Kohno S, Ohue S, Nakamura Y, Kouno D, Ohtsuka Y, Nishikawa M, Matsumoto S, Bernstock JD, Harada S, Mizuno Y, Kitazawa R, Ohnishi T, Kunieda T. Yamashita D, et al. Among authors: ohnishi t. Neurosurg Rev. 2021 Jun;44(3):1591-1600. doi: 10.1007/s10143-020-01348-6. Epub 2020 Jul 15. Neurosurg Rev. 2021. PMID: 32671693 Review.
Focused Ultrasound Thalamotomy for Refractory Essential Tremor: A Japanese Multicenter Single-Arm Study.
Abe K, Horisawa S, Yamaguchi T, Hori H, Yamada K, Kondo K, Furukawa H, Kamada H, Kishima H, Oshino S, Mochizuki H, Kanemoto M, Hirabayashi H, Fukutome K, Ohnishi H, Igase K, Matsubara I, Ohnishi T, Sadamoto K, Taira T. Abe K, et al. Among authors: ohnishi t. Neurosurgery. 2021 Mar 15;88(4):751-757. doi: 10.1093/neuros/nyaa536. Neurosurgery. 2021. PMID: 33469648 Clinical Trial.
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.
Nagane M, Ichimura K, Onuki R, Narushima D, Honda-Kitahara M, Satomi K, Tomiyama A, Arai Y, Shibata T, Narita Y, Uzuka T, Nakamura H, Nakada M, Arakawa Y, Ohnishi T, Mukasa A, Tanaka S, Wakabayashi T, Aoki T, Aoki S, Shibui S, Matsutani M, Ishizawa K, Yokoo H, Suzuki H, Morita S, Kato M, Nishikawa R. Nagane M, et al. Among authors: ohnishi t. Cancers (Basel). 2022 Nov 10;14(22):5522. doi: 10.3390/cancers14225522. Cancers (Basel). 2022. PMID: 36428615 Free PMC article.
What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A, Matsumoto S, Ohnishi T, Miyazaki Y, Kinnami S, Kanno K, Honda T, Kurata M, Taniwaki M, Kusakabe K, Suehiro S, Yamashita D, Shigekawa S, Watanabe H, Kitazawa R, Kunieda T. Inoue A, et al. Among authors: ohnishi t. World Neurosurg. 2023 Apr;172:e517-e523. doi: 10.1016/j.wneu.2023.01.065. Epub 2023 Jan 21. World Neurosurg. 2023. PMID: 36690204
Oct-3/4 promotes tumor angiogenesis through VEGF production in glioblastoma.
Takahashi H, Inoue A, Kawabe Y, Hosokawa Y, Iwata S, Sugimoto K, Yano H, Yamashita D, Harada H, Kohno S, Ohue S, Ohnishi T, Tanaka J. Takahashi H, et al. Among authors: ohnishi t. Brain Tumor Pathol. 2015 Jan;32(1):31-40. doi: 10.1007/s10014-014-0203-3. Epub 2014 Oct 28. Brain Tumor Pathol. 2015. PMID: 25348671
Oct-3/4 promotes migration and invasion of glioblastoma cells.
Kobayashi K, Takahashi H, Inoue A, Harada H, Toshimori S, Kobayashi Y, Goto K, Sugimoto K, Yano H, Ohnishi T, Tanaka J. Kobayashi K, et al. Among authors: ohnishi t. J Cell Biochem. 2012 Feb;113(2):508-17. doi: 10.1002/jcb.23374. J Cell Biochem. 2012. PMID: 21938739
100 results